Evidence map›Paper›PMID 30846487›Full record

ReviewPharmacological reviews2019

Target Site Delivery and Residence of Nanomedicines: Application of Quantitative Systems Pharmacology.

Jessie L-S Au, Roberto A Abbiati, M Guillaume Wientjes, Ze Lu

Abstract readReview
In one paragraph

Review in Pharmacological reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Review
  3. Materials today. Bio · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Deciphering albumin-directed drug delivery by imaging.Advanced drug delivery reviews · 2022
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jessie L-S AuInstitute of Quantitative Systems Pharmacology, Carlsbad, California (J.L.-S.A., R.A.A., M.G.W., Z.L.); Department of Pharmaceutical Sciences, University of Oklahoma, Oklahoma City, Oklahoma (J.L.-S.A., R.A.A.); Optimum Therapeutics LLC, Carlsbad, California (J.L.-S.A., M.G.W., Z.L.); and College of Pharmacy, Taipei Medical University, Taipei, Taiwan, Republic of China (J.L.-S.A.) jau@i-qsp.org.
Roberto A AbbiatiInstitute of Quantitative Systems Pharmacology, Carlsbad, California (J.L.-S.A., R.A.A., M.G.W., Z.L.); Department of Pharmaceutical Sciences, University of Oklahoma, Oklahoma City, Oklahoma (J.L.-S.A., R.A.A.); Optimum Therapeutics LLC, Carlsbad, California (J.L.-S.A., M.G.W., Z.L.); and College of Pharmacy, Taipei Medical University, Taipei, Taiwan, Republic of China (J.L.-S.A.).
M Guillaume WientjesInstitute of Quantitative Systems Pharmacology, Carlsbad, California (J.L.-S.A., R.A.A., M.G.W., Z.L.); Department of Pharmaceutical Sciences, University of Oklahoma, Oklahoma City, Oklahoma (J.L.-S.A., R.A.A.); Optimum Therapeutics LLC, Carlsbad, California (J.L.-S.A., M.G.W., Z.L.); and College of Pharmacy, Taipei Medical University, Taipei, Taiwan, Republic of China (J.L.-S.A.).
Ze LuInstitute of Quantitative Systems Pharmacology, Carlsbad, California (J.L.-S.A., R.A.A., M.G.W., Z.L.); Department of Pharmaceutical Sciences, University of Oklahoma, Oklahoma City, Oklahoma (J.L.-S.A., R.A.A.); Optimum Therapeutics LLC, Carlsbad, California (J.L.-S.A., M.G.W., Z.L.); and College of Pharmacy, Taipei Medical University, Taipei, Taiwan, Republic of China (J.L.-S.A.).

Funding

Targeting multiple signaling steps to achieve synergyR01CA163015 · NCI · OPTIMUM THERAPEUTICS, LLC · PI AU, JESSIE L.-S., WIENTJES, M GUILLAUME · 2012 to 2017
$1.9M
Synergistic chemo-siRNA combination therapyR01CA158300 · NCI · OPTIMUM THERAPEUTICS, LLC · PI AU, JESSIE L.-S., WIENTJES, M GUILLAUME · 2011 to 2015
$1.8M
Rapid release paclitaxel nanoparticles for bladder cancer intravestical therapyR44CA107743 · NCI · OPTIMUM THERAPEUTICS, LLC · PI LU, ZE · 2008 to 2009
$1.8M
Multiscale computational models for developing combination cancer therapyR01GM100487 · NIGMS · OPTIMUM THERAPEUTICS, LLC · PI AU, JESSIE L.-S., WIENTJES, M GUILLAUME · 2011 to 2014
$1.3M
Capturing dynamic and inter-dependent biointerfaces in nanotechnology designsR01EB015253 · NIBIB · OPTIMUM THERAPEUTICS, LLC · PI AU, JESSIE L.-S., WIENTJES, M GUILLAUME · 2011 to 2014
$1.1M
Tumor-priming Microparticles for Pancreatic CancerR44CA103133 · NCI · OPTIMUM THERAPEUTICS, LLC · PI LU, ZE · 2006 to 2012
$1.1M
Bladder Tumor Targeting by Intravesical PaclitaxelR43CA107743 · NCI · OPTIMUM THERAPEUTICS, LLC · PI LU, ZE · 2004 to 2005
$600k
Apoptosis Inducing to Enhance Tumor TargetingR43CA103133 · NCI · OPTIMUM THERAPEUTICS, LLC · PI LU, ZE · 2003 to 2004
$496k
Combination chemo-siRNA gene therapy of nonmuscle-invading bladder cancerR43TR000356 · NCATS · OPTIMUM THERAPEUTICS, LLC · PI AU, JESSIE L.-S., LU, ZE · 2012 to 2012
$344k
Intra-bladder MMC & suramin for nonmuscle-invading & locally advanced bladder caR43CA162448 · NCI · OPTIMUM THERAPEUTICS, LLC · PI AU, JESSIE L.-S., LU, ZE · 2011 to 2012
$303k
NCATS NIH HHS R43 TR000356NCI NIH HHS R01 CA158300NCI NIH HHS R01 CA163015NCI NIH HHS R43 CA103133NCI NIH HHS R43 CA107743NCI NIH HHS R43 CA162448NCI NIH HHS R44 CA103133NCI NIH HHS R44 CA107743NIBIB NIH HHS R01 EB015253NIGMS NIH HHS R01 GM100487
6 · The paper itself

Abstract

Quantitative systems pharmacology (QSP), an emerging field that entails using modeling and computation to interpret, interrogate, and integrate drug effects spanning from the molecule to the whole organism to forecast treatment outcomes, is expected to enhance the efficiency of drug development. Since late 2017, the U.S. Food and Drug Administration has advocated the use of an analogous approach of model-informed drug development. This review focuses on issues pertaining to nanosized medicines (NP) and the potential utility of QSP to determine NP delivery and residence at extracellular or intracellular targets in vivo. The kinetic processes governing NP disposition and transport, interactions with biologic matrix components, binding and internalization in cells, and intracellular trafficking are determined, sometimes jointly, by NP properties (e.g., dimension, materials, surface charge and modifications, shape, and geometry) and target tissue properties (e.g., perfusion status, vessel pore size and wall thickness, vessel and cell density, composition of extracellular matrix, and void volume fraction). These various determinants, together with the heterogeneous tissue structures and microenvironment factors in solid tumors, lead to environment-, spatial-, and time-dependent changes in NP concentrations that are difficult to predict. Adding to the complexity is the recent discovery that NP surface-coating protein corona, whose composition depends on NP properties and which undergoes continuous evolution with time and local protein environments, is yet another unpredictable variable. Examples are provided to demonstrate the potential utility of QSP-based multiscale modeling to capture the physicochemical and biologic processes in equations to enable computational studies of the key kinetic processes in cancer treatments.

Indexed as

Drug Delivery SystemsAnimalsDrug DevelopmentHumansModels, TheoreticalNanomedicineNanostructuresNeoplasmsPharmacologySystems BiologyTime FactorsTumor Microenvironment

Identifiers

PMID30846487
PMCPMC6407667

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.